These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 739057)

  • 21. Early experience with the use of anti-inhibitor coagulant complex to treat bleeding in hemophiliacs with inhibitors to factor VIII.
    Kantrowitz JL; Lee ML; McClure DA; Kingdon HS; Thomas WR
    Clin Ther; 1987; 9(4):405-19. PubMed ID: 3111706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Manifestations of factor VIII inhibitor in the head and neck.
    DellaCroce FJ; Kountakis S; Aguilar EF
    Arch Otolaryngol Head Neck Surg; 1999 Nov; 125(11):1258-61. PubMed ID: 10555699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemophiliacs with inhibitors: therapeutic options.
    Roberts HR
    N Engl J Med; 1981 Sep; 305(13):757-8. PubMed ID: 6790992
    [No Abstract]   [Full Text] [Related]  

  • 25. Factor VIII inhibitors in hemophilia.
    Mariani G
    Bilt Hematol Transfuz; 1979; 7(1):3-41. PubMed ID: 121880
    [No Abstract]   [Full Text] [Related]  

  • 26. Haemophilic patients with inhibitors to factor VIII or IX: variables affecting treatment response.
    Penner JA
    Haemophilia; 2001 Jan; 7(1):103-8. PubMed ID: 11136390
    [No Abstract]   [Full Text] [Related]  

  • 27. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors.
    Hilgartner MW; Knatterud GL
    Blood; 1983 Jan; 61(1):36-40. PubMed ID: 6401216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Inhibitor hemophilia in oral surgery].
    Schulz S
    Zahn Mund Kieferheilkd Zentralbl; 1984; 72(8):824-8. PubMed ID: 6240865
    [No Abstract]   [Full Text] [Related]  

  • 29. The use of non-activated prothrombin concentrate in the management of haemophilia A with factor VIII antibodies.
    Price DA; d'Souza S; Ekert H
    Aust N Z J Med; 1977 Jun; 7(3):286-90. PubMed ID: 269689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agarose gel method: its usefulness in assaying factor VIII inhibitors, evaluating treatment and suggesting a mechanism of action for factor IX concentrates.
    Coots MC; Glueck HI; Miller MA
    Br J Haematol; 1985 Aug; 60(4):735-50. PubMed ID: 3927972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FEIBA safety profile in multiple modes of clinical and home-therapy application.
    Luu H; Ewenstein B
    Haemophilia; 2004 Sep; 10 Suppl 2():10-6. PubMed ID: 15385041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antihemophilic factor inhibitors. Management with prothrombin complex concentrates.
    Kelly P; Penner JA
    JAMA; 1976 Nov; 236(18):2061-4. PubMed ID: 989788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of factor VIII inhibitors: evolution and current status.
    Bloom AL
    Haemostasis; 1992; 22(5):268-75. PubMed ID: 1478538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX.
    Tjønnfjord GE; Brinch L; Gedde-Dahl T; Brosstad FR
    Haemophilia; 2004 Mar; 10(2):174-8. PubMed ID: 14962207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
    Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD
    Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX].
    Iizuka A; Kuwashima M; Nagao T
    Nihon Ketsueki Gakkai Zasshi; 1982 Sep; 45(5):987-92. PubMed ID: 6818811
    [No Abstract]   [Full Text] [Related]  

  • 37. [Prophylaxis in patients with haemophilia complicated by inhibitors].
    Paweł Ł
    Pol Merkur Lekarski; 2011 Mar; 30(177):211-4. PubMed ID: 21545000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of anti-factor VIII antibodies.
    Blatt PM; White GC; McMillan CW; Roberts HR
    Thromb Haemost; 1977 Aug; 38(2):514-23. PubMed ID: 579493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Failure of activated prothrombin complex concentrates in a hemophiliac with an anti-factor VIII antibody.
    Blatt PM; White GC; McMillan CW; Webster WP
    JAMA; 1984 Jan; 251(1):67. PubMed ID: 6418898
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibitor development in patients with hemophilia: an overview.
    Leissinger CA
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S1-2. PubMed ID: 16690370
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.